# DEA Moves to Schedule Four Emerging Synthetic Opioids > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/brorphine-schedule-i-dea-four-synthetic-opioids/ > **Published:** 2026-07-06T10:51:07-04:00 | **Last Modified / Clinically Audited:** 2026-09-13T20:04:18-04:00 > **Clinical Summary:** Brorphine Schedule I action moves closer as DEA targets four emerging synthetic opioids and clarifies how federal drug scheduling works --- Federal Drug Policy Watch Table of Contents - [DEA Is Moving Four New Synthetic Opioids Toward Schedule I. Here’s What That Actually Means.](#DEA_Is_Moving_Four_New_Synthetic_Opioids_Toward_Schedule_I_Heres_What_That_Actually_Means)[What has actually happened?](#What_has_actually_happened) - [Why is DEA acting now?](#Why_is_DEA_acting_now) - [Brorphine Schedule I: DEA Targets Four Emerging Synthetic Opioids](#Brorphine_Schedule_I_DEA_Targets_Four_Emerging_Synthetic_Opioids) - [Why the Brorphine Schedule I Action Matters](#Why_the_Brorphine_Schedule_I_Action_Matters)[The part cannabis policy observers should notice](#The_part_cannabis_policy_observers_should_notice) - [Why this matters](#Why_this_matters) - [Related](#Related) ## DEA Is Moving Four New Synthetic Opioids Toward Schedule I. Here’s What That Actually Means. The Drug Enforcement Administration has formally announced its intent to temporarily place four emerging synthetic opioids into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act: **5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine**. These are not [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/). They are novel synthetic opioids in a group sometimes called the **“orphines”**, chemically and pharmacologically related to drugs such as brorphine and acting through the mu-opioid receptor system. In simpler terms, this is part of the same broad pharmacologic world that makes fentanyl and other potent opioids capable of producing euphoria, physical dependence, and dangerous respiratory suppression. ### What has actually happened? On July 1, 2026, DEA published a formal **notice of intent** to use its emergency temporary-scheduling authority. This is not yet the final temporary scheduling order. DEA says that order may be published on or after **July 31, 2026**. Once the order is published, the four substances would immediately become subject to federal Schedule I controls. ### Why is DEA acting now? ## Brorphine Schedule I: DEA Targets Four Emerging Synthetic Opioids DEA says these compounds are beginning to appear in illicit drug seizures and toxicology testing, sometimes mixed with substances including fentanyl, xylazine, medetomidine, benzodiazepines, methamphetamine, and cocaine. That matters because the person consuming the product may have no idea the newer opioid is present. ## Why the Brorphine Schedule I Action Matters The clearest warning signal involves **N-propionitrile chlorphine, also called cychlorphine**. DEA reports 225 forensic encounters across 19 states since 2022 and says its expanded toxicology program has identified the drug in **49 fatalities**. In one published nonfatal case, a 36-year-old man reportedly inhaled what he believed was alprazolam. Testing instead identified a mixture primarily containing N-propionitrile chlorphine along with fentanyl and xylazine. This is the familiar danger of the modern unregulated drug supply: **the label in someone’s mind and the chemistry in the product may be entirely different things.** ### The part cannabis policy observers should notice The most interesting part of this notice may actually be the legal language DEA uses to justify Schedule I. DEA specifically discusses whether these drugs have a **“currently accepted medical use”** in the United States and cites the Justice Department Office of Legal Counsel’s April 11, 2024 opinion concerning the federal marijuana rescheduling process. That opinion addressed the test HHS may use to determine whether a substance has an accepted medical use. For these four synthetic opioids, the answer appears straightforward. HHS told DEA that there are no approved new drug applications or investigational new drug applications for the substances, and DEA says there is no evidence of widespread medical use recognized by health care providers or medical regulators. That is a profoundly different factual record from cannabis. Yet the same statutory vocabulary is being used: **abuse potential, accepted medical use, and safety under medical supervision.** Watching how federal agencies apply those words to very different substances remains important because scheduling is not simply a scientific classification system. It is a [legal framework](https://cedclinic.com/ohio-cannabis-law-changes-impact-patient-access/) that attempts to translate pharmacology, public-health data, patterns of use, and medical practice into regulatory categories. ### Why this matters On the public-health side, this is an early-warning story. New synthetic opioids can move through the [illicit market](https://cedclinic.com/illicit-cannabis-market-risks-columbia-county-seizure/) faster than routine toxicology systems learn to identify them. DEA itself acknowledges that commonly used screening methods may fail to detect these compounds, meaning some overdoses or deaths may go unrecognized. On the policy side, this is another useful window into how the federal government decides that a drug belongs in Schedule I. In this case, DEA is invoking an expedited authority designed for an **“imminent hazard to [public safety](https://cedclinic.com/virginia-marijuana-impaired-driving-campaign/).”** Temporary scheduling can last two years, with a possible additional one-year extension while the government considers permanent control. It is worth paying attention to the distinction. **Not every Schedule I story is the same story.** Four newly emerging opioids associated with clandestine drug markets, unsuspected exposure, respiratory risk, and dozens of toxicology-confirmed fatalities present a very different scientific and medical question from a substance used by millions of patients and discussed within established state medical systems. The schedule number may be the same. The evidence underneath it can be radically different. Those details matter. **Primary source:** U.S. Drug Enforcement Administration. *Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act.* 91 Fed. Reg. 39940. Published July 1, 2026. Document No. 2026-13364.[Read the Federal Register notice](https://www.federalregister.gov/documents/2026/07/01/2026-13364/schedules-of-controlled-substances-temporary-placement-of-56--dichloro-brorphine-56-dichloro) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).